Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2‘-Fluoro-3‘-(substituted phenyl)deschloroepibatidine Analogues. Novel Nicotinic Antagonist

A series of 2‘-fluoro-3‘-(substituted phenyl)deschloroepibatidine analogues (5a − k) showed high affinity for α4β2 binding with no affinity at α7 nAChRs. The most potent compound was 2‘-fluoro-3‘-(4-nitrophenyl)deschloroepibatidine (5g) which possessed a K i value of 0.009 nM. Surprisingly, none of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2004-08, Vol.47 (18), p.4588-4594
Hauptverfasser: Carroll, F. Ivy, Ware, Roy, Brieaddy, Lawrence E, Navarro, Hernán A, Damaj, M. I, Martin, Billy R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A series of 2‘-fluoro-3‘-(substituted phenyl)deschloroepibatidine analogues (5a − k) showed high affinity for α4β2 binding with no affinity at α7 nAChRs. The most potent compound was 2‘-fluoro-3‘-(4-nitrophenyl)deschloroepibatidine (5g) which possessed a K i value of 0.009 nM. Surprisingly, none of the compounds showed agonist effects in pain tests and body temperature changes in mice even when tested at 10−15 mg/kg with the exception of 5b, which showed only very weak agonist effects. In contrast, all the compounds were potent functional antagonists of nicotine-induced antinociception. Interestingly, the 3‘-substituted phenyl analogues 5b − k were 10−870-fold more effective as antagonists in the tail-flick test versus the hot-plate procedure. They failed to antagonize nicotine-induced hypothermia. The 4-chlorophenyl analogue (5e) (AD50 = 0.0003 in the tail-flick test) was the most potent and selective analogue. These results suggest that these compounds will be highly useful for identifying which specific receptor subtypes are involved in each of nicotine's pharmacological effects. These compounds also deserve consideration as potential pharmacotherapies for treatment of smoking cessation.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm040078g